MLTO Medirect Latino Inc (CE)

MEDirect Latino Inc. (OTC:MLTO) - http://www.medirectlatino.org - today, reported a 60 percent increase over projected customer response rate for its media campaign focused on Medicare eligible direct to consumer diabetic customers in Puerto Rico in the month of June 2005. The Company has implemented additional infrastructure and hired additional Diabetic Customer Care Specialists to handle added volume of sales resulting from the Company's increasing focus on the Puerto Rico Market. Sales of the Company's proprietary branded line of Dialogistic Testing supplies increased 78% over the previous month's results. The Company anticipated an increase of sales as a result of the comprehensive media rollout, and worked directly with pharmaceutical suppliers and manufactures to maintain sufficient product inventory levels to meet the customer demands. MEDirect Latino maintains just-in-time inventory controls which compliments the Medicare reimbursable model. The Company's distribution center, at full capacity, can process 5000 customer orders weekly. Based upon the customer demand, which has exceeded the Company's projections, MEDirect Latino is anticipating generating gross revenues of $10,190,956 within the next 12 months and EBITDA of approximately $3,000,000. MEDirect Latino is a rapidly growing, 3-year-old, federally licensed national provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico. MEDirect is uniquely positioned to serve the U.S. Hispanic healthcare market as a direct-to-consumer Medicare provider. In discussing the success of the campaign in Puerto Rico, Chief Operating Officer of MLTO, Mr. Charles W. Hansen III, stated: "We can now confirm our anticipated customer response results with true numbers of calls received and customers closed during June's media campaign and they have far exceeded our expectations. In closing, Management has a comfort level with our expectations for our national media rollout with the networks of Univision and Telemundo in July." About MEDirect Latino: MEDirect Latino (OTC:MLTO) - http://www.medirectlatino.org - is a rapidly growing, uniquely positioned provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico. MEDirect is the only company positioned to serve the U.S. Hispanic healthcare market as a direct-to-consumer Medicare provider on an authentically national level. The Company's current focus is the distribution of products for the treatment of Type II diabetes specifically because of its disproportionate impact and increasing diagnosis rate within the US Hispanic population, noting an incidence of 120% higher than among non-Hispanic whites. Type II diabetes was also targeted because of its unique status within the Medicare reimbursement regime and because of its high degree of correlation to other chronic conditions such as high blood pressure and heart disease. These other conditions represent considerable future market potential that will allow MEDirect to efficiently scale its model by leveraging its existing client base and infrastructure. The current Hispanic market for MEDirect's products is conservatively estimated at approximately $650MM in the continental United States. The size of the opportunity is understated by such figures as an estimated 925,000 of the over 3.1 million Hispanics in the United States over 65 eligible to receive Medicare benefits are currently collecting these benefits with an estimate that over 1.4 million of those Medicare-eligible Hispanics have diabetes (implying a potential continental U.S. market for MEDirect products of approximately $1 billion). Forward-Looking Statements: Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. The Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this press release, the Company will appropriately inform the public.